Acute Myeloid Leukaemia Committee (AML)

Acute Myeloid Leukemia Committee (AML)

Abstract

Outcomes of children with acute myeloid leukemia (AML) have improved significantly in the past decades among others through efforts of cooperative groups, an intense collaboration and the coordination of research efforts. The I-BFM AML committee is a working group that unites doctors, biologists and researchers interested in pediatric acute myeloid disease and/or involved in treatment of patients with acute myeloid malignancies, such as AML and acute promyelocytic leukemia, Down syndrome associated leukemia and myeloproliferative disease. The mission of the I-BFM AML committee is the improvement of outcome and quality of life of children and adolescents with acute myeloid malignancies by promoting and advancing knowledge and exchanging information. The I-BFM AML committee is an interface between the various national and international cooperative groups, the research teams and organizations focused on innovative treatment such as ITCC (Innovative Therapies for Children with Cancer) and EUPAL (EUropean Pediatric Acute Leukemia) initiative.

• AAML1831

  Frontline protocol (COG)

• AIEOP-AML-BFM 2020

  Frontline protocol (BFM, AIEOP)

• AMoRe 2017

  For molecular relapsed AML patients

• EuPAL trials

  For relapsed AML patients and early phase trials for relapsed AML (ITCC)

• ICC APL study 02

  For newly diagnosed APL patients

• JPLSG-AML-20

  Frontline protocol (JCCG)

• JPLSG-AML-D16

  For newly diagnosed Down syndrome patients with myeloid leukemia (JCCG)

• JPLSG-AML-P13

  For newly diagnosed APL patients (JCCG)

• ML-DS 2018

  For newly diagnosed Down syndrome patients with myeloid leukemia

• MyeChild01

  Frontline protocol (SFCE, CCLG, Ireland, Australia, Switzerland)

• NOPHO-DBH AML 2012

  Frontline protocol (NOPHO DH SHIP)

• PedAL trials

  For relapsed AML patients and early phase trials for relapsed AML (COG)

Selected publications, from 2023 onwards